Ranibizumab and the Risk of Arterial Thromboembolic Events
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 380 participants.
Also called NCT01319188
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose screening
- Phase
- Phase 4
- Enrolled
- 380 participants
- Sponsor
- Ural State Medical University
- Registry
-
NCT01319188
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Netherlands, Russia
- Registry status
- Terminated
Technical summary
Registry record NCT01319188. Randomized; double masking; primary purpose screening. Start 2010-06 (registry gives no type); primary completion 2012-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ranibizumab and the Risk of Arterial Thromboembolic Events
- Acronym
- RATE
- Condition
- Age-related Macular Degeneration
- Condition
- Coronary Artery Disease
- Condition
- Cerebrovascular Disorders
- Intervention (Drug)
- 0.5 mg of ranibizumab
- Intervention (Procedure)
- 0.5 mg of ranibizumab + photodynamic therapy
- Intervention (Other)
- Sham injection
- Lead sponsor
- Ural State Medical University
- Collaborator
- Ural Institute of Cardiology
- Collaborator
- De Haar Research Foundation
Record details
- Record id
cardio:ct-nct01319188- Content hash
0430c278f7a13df2bbc591fbbd4ed5071bf51439f31d04c782647752bf3d4a74